Accessibility Menu
Vitrolife Ab (publ) logo

Vitrolife Ab (publ)(OTC) VTRLY

Current Price$9.50
Market Cap$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-17%
5 Year-62%
1 Year-36%
1 Month-14%
Vitrolife Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 9.502026-07-09
Vitrolife Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.45%USD 11.372026-07-02
1 month-13.64%USD 11.002026-06-04
3 month-12.7%USD 10.882026-04-09
Year to date-36.26%USD 14.902025-12-29
1 year-35.89%USD 14.822025-07-02
3 year-49.71%USD 18.892023-06-27
5 year-61.66%USD 24.782021-02-04
Since inception-17.28%USD 11.482016-08-10

Vitrolife Ab (publ) Financials at a Glance

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 3.38B

Net Income (TTM)

-SEK 4.98B

EPS (TTM)

-$3.91

P/E Ratio

-2.43

Dividend

$0.12

Beta (Volatility)

0.07 (Low)

Price

$9.50

Volume

225

Open

$9.50

Previous Close

$9.50

Daily Range

$9.50 - $9.50

52-Week Range

$9.50 - $18.55

Estimated Earnings Date

Apr 22, 2026

VTRLY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vitrolife Ab (publ)

Vitrolife AB (publ) is a Swedish medical technology company specializing in products for assisted reproductive technologies (ART). Established in 1994 and headquartered in Gothenburg, the company offers a comprehensive range of solutions for in vitro fertilization (IVF) and related laboratory needs.

Products and Services
  • Specialized tools for IVF, including oocyte retrieval needles and culture media
  • Advanced time-lapse systems for embryo evaluation, such as EmbryoScope
  • Laboratory necessities, including incubators and cryopreservation products
Growth Outlook
  • Strong demand for ART products is expected to drive revenue growth
  • Expansion into emerging markets enhances global reach and market share
  • Continuous investment in R&D supports innovation and product development
Financial Highlights
  • Recent quarterly revenue of 807 million SEK, reflecting a solid performance
  • Gross profit margin improved to 59.85% in the latest quarter
  • Cash and cash equivalents reached 886 million SEK, ensuring liquidity
Vitrolife AB (publ) operates in a growing sector, driven by increasing infertility rates and advancements in reproductive technologies. The company's diverse product portfolio positions it well to capitalize on market opportunities. Recent financial performance indicates resilience, with a notable gross profit margin and healthy cash reserves. The focus on research and development is expected to foster innovation, further enhancing the company's competitive edge. As Vitrolife continues to expand its global footprint, it remains well-positioned for sustained growth in the medical technology industry.
AI Generated • Jul 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,103

CEO

Bronwyn Brophy O'Connor

Website

www.vitrolife.com

Headquarters

Gothenburg, VG 421 32, SE

VTRLY Financials

Key Financial Metrics (TTM)

Gross Margin

53.72%

Operating Margin

19.50%

Net Income Margin

-146.96%

Return on Equity

-53.29%

Return on Capital

6.10%

Return on Assets

-44.08%

Earnings Yield

-41.15%

Dividend Yield

1.24%

Payout Ratio

-2.99%

Stock Overview

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

135.42M

Volume

225

Avg. Volume

22.081

Financials (TTM)

Gross Profit

SEK 1.94B

Operating Income

-SEK 4.77B

EBITDA

-SEK 4.54B

Operating Cash Flow

SEK 720.19M

Capital Expenditure

-SEK 207.14M

Free Cash Flow

SEK 513.19M

Cash & ST Invst.

SEK 823.00M

Total Debt

SEK 1.60B

Vitrolife Ab (publ) Performance Analysis

Vitrolife Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 319,568,58363.2%
20232023-12-31SEK 330,823,1483.5%
20242024-12-31SEK 341,349,8403.2%
20252025-12-31SEK 350,751,6572.8%
Vitrolife Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.5%
Q42025-12-318.3%
Q12026-03-31-9.4%
Q22026-06-306.2%
Vitrolife Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 0.29-17.0%
20232023-12-31SEK -2.68N/A
20242024-12-31SEK 0.36N/A
20252025-12-31SEK -3.77N/A
Vitrolife Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-5402.7%
Q12026-03-31101.9%
Q22026-06-3028.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 857.00M

-1.6%

Gross Profit

SEK 517.00M

+2.4%

Gross Margin

60.33%

N/A

Market Cap

$1.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.14M

N/A

Employees

1,126

N/A

Net Income

SEK 129.00M

+29.0%

EBITDA

SEK 258.00M

+74.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 823.00M

-10.6%

Total Debt

SEK 1.60B

-19.7%

Accounts Receivable

SEK 909.00M

+18.2%

Inventory

SEK 440.00M

+2.3%

Long Term Debt

SEK 1.56B

-15.4%

Short Term Debt

SEK 45.00M

-70.6%

Return on Assets

-44.08%

N/A

Return on Invested Capital

6.18%

N/A

Free Cash Flow

SEK 106.00M

-24.8%

Operating Cash Flow

SEK 140.00M

-7.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNNDYGN Store Nord A/S
$41.74+0.07%
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
BRCTFBioArctic AB (publ)
$31.78+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About VTRLY

What is the current price of Vitrolife Ab (publ)?

Vitrolife Ab (publ) is trading at $9.50 per share.

What is the 52-week range for Vitrolife Ab (publ)?

Over the past 52 weeks, Vitrolife Ab (publ) has traded between $9.50 and $18.55.

How much debt does Vitrolife Ab (publ) have?

As of the most recent reporting period, Vitrolife Ab (publ) reported total debt of SEK 165.42M.

How much cash does Vitrolife Ab (publ) have on hand?

Vitrolife Ab (publ) reported SEK 85.04M in cash and cash equivalents in its most recent financial results.

What is Vitrolife Ab (publ)’s dividend yield?

Vitrolife Ab (publ) currently has a dividend yield of 1.24%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services